Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
393 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016', provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) - The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects - The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Congestive Heart Failure (Heart Failure) Overview 12 Therapeutics Development 13 Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview 13 Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis 14 Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies 15 Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes 21 Congestive Heart Failure (Heart Failure) - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Congestive Heart Failure (Heart Failure) - Products under Development by Companies 27 Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes 34 Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 36 Amgen Inc. 36 AnGes MG, Inc. 37 Araim Pharmaceuticals, Inc. 38 ARCA biopharma, Inc. 39 Ascelegen Therapeutics, Inc. 40 Asterias Biotherapeutics, Inc. 41 Athersys, Inc. 42 Bayer AG 43 BEAT BioTherapeutics Corp. 44 BioCardia, Inc. 45 Bristol-Myers Squibb Company 46 Capricor Therapeutics, Inc. 47 Cell Therapy Limited 48 Celyad SA 49 Eli Lilly and Company 50 FibroGen, Inc. 51 GlaxoSmithKline Plc 52 Glucox Biotech AB 53 Heart Metabolics Limited 54 Hemostemix Ltd 55 Innopharmax Inc. 56 Jiangsu Hengrui Medicine Co., Ltd. 57 Juventas Therapeutics, Inc. 58 La Jolla Pharmaceutical Company 59 Laboratoires Pierre Fabre SA 60 Lead Discovery Center GmbH 61 Lee's Pharmaceutical Holdings Limited 62 Les Laboratoires Servier SAS 63 Lonestar Heart, Inc. 64 Mast Therapeutics, Inc. 65 Merck & Co., Inc. 66 Mesoblast Limited 67 miRagen Therapeutics, Inc. 68 MorphoSys AG 69 NanoCor Therapeutics, Inc. 70 Neurocrine Biosciences, Inc. 71 Novartis AG 72 Nuo Therapeutics, Inc. 73 Ono Pharmaceutical Co., Ltd. 74 Palatin Technologies, Inc. 75 Pfizer Inc. 76 PharmaIN Corporation 77 PhaseBio Pharmaceuticals, Inc. 78 Pluristem Therapeutics Inc. 79 Quantum Genomics SA 80 Recardio GmbH 81 RedHill Biopharma Ltd. 82 Renova Therapeutics Inc 83 scPharmaceuticals Inc 84 Stealth BioTherapeutics Inc. 85 Stemedica Cell Technologies, Inc. 86 Target Heart Biotec Srl 87 Theravance Biopharma, Inc. 88 TiGenix NV 89 Torrent Pharmaceuticals Limited 90 Trevena, Inc. 91 U.S. Stem Cell, Inc. 92 Vichem Chemie Research Ltd. 93 Vicore Pharma AB 94 Zensun (Shanghai) Sci & Tech Co., Ltd. 95 Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 96 Assessment by Monotherapy Products 96 Assessment by Combination Products 97 Assessment by Target 98 Assessment by Mechanism of Action 104 Assessment by Route of Administration 110 Assessment by Molecule Type 112 Drug Profiles 114 (sacubitril + valsartan) - Drug Profile 114 AAVS-100A1 - Drug Profile 119 ACP-01 - Drug Profile 121 AdipoCell - Drug Profile 124 aladorian sodium - Drug Profile 127 ALD-201 - Drug Profile 129 AMG-986 - Drug Profile 131 AntimiR-199a - Drug Profile 132 ARX-720 - Drug Profile 133 BAY-868050 - Drug Profile 134 BBR-12 - Drug Profile 135 beperminogene perplasmid - Drug Profile 136 BMS-986231 - Drug Profile 141 bucindolol hydrochloride - Drug Profile 142 C-21 - Drug Profile 149 C3BSCQR-1 - Drug Profile 151 CAP-1002 - Drug Profile 156 Carfostin - Drug Profile 161 carvedilol CR - Drug Profile 162 carvedilol phosphate CR - Drug Profile 164 cenderitide - Drug Profile 165 cibinetide - Drug Profile 168 CLR-325 - Drug Profile 171 CM-1 - Drug Profile 172 CTX-101 - Drug Profile 174 Drug to Inhibit Calpain for Heart Failure - Drug Profile 176 Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure - Drug Profile 177 Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 178 ECR-A1 - Drug Profile 179 elamipretide - Drug Profile 180 enalapril maleate - Drug Profile 187 F-373280 - Drug Profile 188 FG-6874 - Drug Profile 189 FG-8205 - Drug Profile 190 furosemide - Drug Profile 191 GDF-11 - Drug Profile 193 Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 194 Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile 195 Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 196 Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 197 Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile 198 Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 199 GSK-2798745 - Drug Profile 200 istaroxime - Drug Profile 201 ITD-1 - Drug Profile 203 ivabradine hydrochloride - Drug Profile 204 ivabradine hydrochloride SR - Drug Profile 206 JVS-100 - Drug Profile 207 KBP-5074 - Drug Profile 212 L-2286 - Drug Profile 213 MGN-9103 - Drug Profile 214 milrinone ER - Drug Profile 216 Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure - Drug Profile 217 MP-3167 - Drug Profile 218 MPC-150IM - Drug Profile 219 MRS-2339 - Drug Profile 224 MyoCell - Drug Profile 225 MyoCell SDF-1 - Drug Profile 227 NBI-69734 - Drug Profile 228 neladenoson bialanate - Drug Profile 229 Neucardin - Drug Profile 230 NM-922 - Drug Profile 233 NPA-7 - Drug Profile 234 Oligonucleotides for Heart Failure - Drug Profile 235 omecamtiv mecarbil MR - Drug Profile 236 ONO-4232 - Drug Profile 243 PB-1046 - Drug Profile 244 Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 246 Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 247 perhexiline maleate - Drug Profile 248 PF-05285401 - Drug Profile 250 PHIN-1138 - Drug Profile 261 PL-3994 - Drug Profile 262 PLX-PAD - Drug Profile 264 poloxamer - Drug Profile 273 pyroglutaminated serpinin - Drug Profile 275 QGC-101 - Drug Profile 276 REC-02 - Drug Profile 277 Recombinant Protein for Congestive Heart Failure - Drug Profile 278 rivaroxaban - Drug Profile 279 RT-100 - Drug Profile 293 RT-110 - Drug Profile 294 RT-300 - Drug Profile 295 RT-400 - Drug Profile 296 ruboxistaurin - Drug Profile 297 S-38844 - Drug Profile 299 serelaxin - Drug Profile 300 serpinin - Drug Profile 304 SG-1002 - Drug Profile 305 sildenafil citrate - Drug Profile 306 Small Molecule for Target RhoGEF12 for Cardiovascular Disease - Drug Profile 308 Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 309 Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 310 Small Molecule to Inhibit ROMK for Hypertension and Heart Failure - Drug Profile 311 Small Molecules for Chronic Heart Failure - Drug Profile 312 Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 313 Small Molecules for Diastolic Heart Failure - Drug Profile 314 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 315 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 316 Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 317 Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 318 Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 319 Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 320 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 321 Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 322 sodium nitrite - Drug Profile 323 SP-20202 - Drug Profile 326 Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 327 Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 332 Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 333 Stem Cell Therapy for Heart failure - Drug Profile 334 Stem Cell Therapy for Heart Failure - Drug Profile 335 Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 336 Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 337 Synthetic Peptide to Agonise Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 338 Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 339 TD-0714 - Drug Profile 340 TR-4 - Drug Profile 342 TRC-4186 - Drug Profile 343 TRV-120023 - Drug Profile 345 ularitide - Drug Profile 346 VCP-746 - Drug Profile 348 vepoloxamer - Drug Profile 349 vericiguat - Drug Profile 357 Xcel-hCardP - Drug Profile 358 XEN-105 - Drug Profile 359 Congestive Heart Failure (Heart Failure) - Dormant Projects 360 Congestive Heart Failure (Heart Failure) - Discontinued Products 370 Congestive Heart Failure (Heart Failure) - Product Development Milestones 372 Featured News & Press Releases 372 Appendix 383 Methodology 383 Coverage 383 Secondary Research 383 Primary Research 383 Expert Panel Validation 383 Contact Us 383 Disclaimer 384
List of Tables
Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2016 22 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2016 23 Number of Products under Development by Companies, H2 2016 25 Number of Products under Development by Companies, H2 2016 (Contd..1) 26 Number of Products under Development by Companies, H2 2016 (Contd..2) 27 Number of Products under Development by Companies, H2 2016 (Contd..3) 28 Number of Products under Development by Companies, H2 2016 (Contd..4) 29 Number of Products under Investigation by Universities/Institutes, H2 2016 31 Comparative Analysis by Late Stage Development, H2 2016 32 Comparative Analysis by Clinical Stage Development, H2 2016 33 Comparative Analysis by Early Stage Development, H2 2016 34 Comparative Analysis by Unknown Stage Development, H2 2016 35 Products under Development by Companies, H2 2016 36 Products under Development by Companies, H2 2016 (Contd..1) 37 Products under Development by Companies, H2 2016 (Contd..2) 38 Products under Development by Companies, H2 2016 (Contd..3) 39 Products under Development by Companies, H2 2016 (Contd..4) 40 Products under Development by Companies, H2 2016 (Contd..5) 41 Products under Development by Companies, H2 2016 (Contd..6) 42 Products under Investigation by Universities/Institutes, H2 2016 43 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 44 Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H2 2016 45 Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H2 2016 46 Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 47 Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H2 2016 48 Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H2 2016 49 Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 50 Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H2 2016 51 Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2016 52 Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H2 2016 53 Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc., H2 2016 54 Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2016 55 Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc., H2 2016 56 Congestive Heart Failure (Heart Failure) - Pipeline by Cell Therapy Limited, H2 2016 57 Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H2 2016 58 Congestive Heart Failure (Heart Failure) - Pipeline by Eli Lilly and Company, H2 2016 59 Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H2 2016 60 Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H2 2016 61 Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H2 2016 62 Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited, H2 2016 63 Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H2 2016 64 Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H2 2016 65 Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 66 Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H2 2016 67 Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2016 68 Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 69 Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H2 2016 70 Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 71 Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2016 72 Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H2 2016 73 Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H2 2016 74 Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H2 2016 75 Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H2 2016 76 Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H2 2016 77 Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H2 2016 78 Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics, Inc., H2 2016 79 Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences, Inc., H2 2016 80 Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H2 2016 81 Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc., H2 2016 82 Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 83 Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H2 2016 84 Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H2 2016 85 Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H2 2016 86 Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 87 Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H2 2016 88 Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H2 2016 89 Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2016 90 Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H2 2016 91 Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H2 2016 92 Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H2 2016 93 Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc., H2 2016 94 Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 95 Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H2 2016 96 Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc., H2 2016 97 Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H2 2016 98 Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 99 Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H2 2016 100 Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc., H2 2016 101 Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd., H2 2016 102 Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2016 103 Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 104 Assessment by Monotherapy Products, H2 2016 105 Assessment by Combination Products, H2 2016 106 Number of Products by Stage and Target, H2 2016 108 Number of Products by Stage and Mechanism of Action, H2 2016 114 Number of Products by Stage and Route of Administration, H2 2016 120 Number of Products by Stage and Molecule Type, H2 2016 122 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2016 369 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H2 2016 370 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H2 2016 371 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H2 2016 372 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H2 2016 373 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H2 2016 374 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H2 2016 375 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H2 2016 376 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..8), H2 2016 377 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..9), H2 2016 378 Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2016 379 Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H2 2016 380
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
